Trials / Unknown
UnknownNCT02184897
Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization
Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization in Patients With Multiple Myeloma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Twenty four patients with multiple myeloma will be randomized to either AM group (administration of lenograstim at 8 am) or PM group (administration of lenograstim at 6 am ). Apheresis of hematopoietic stem cell will start at 10 am on D5 in AM group and at 8 am on D4 in PM group, respectively. Pharmacokinetic data of lenograstim will be correlated with pharmacodynamic data of CD34+ cell count, absolute neutrophil cell count and hematopoeitic progenitor cell count. In addition, the yield of stem cell collection between two arms will be analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenograstim 10 microgram/kg/day |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-08-01
- Completion
- 2016-12-01
- First posted
- 2014-07-09
- Last updated
- 2016-07-26
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02184897. Inclusion in this directory is not an endorsement.